July 17, 2013

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Chris Parker

Sten Nilsson

Daniel Heinrich

Journals

New England Journal of Medicine

Actions

Institutions

Royal Marsden NHS Foundation Trust

San Antonio College

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study